TY - JOUR A1 - Öhlschläger, Peter A1 - Osen, Wolfram A1 - Peiler, Tanja A1 - Caldeira, Sandra T1 - A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity / Osen, Wolfram ; Peiler, Tanja ; Öhlschläger, Peter ; Caldeira, Sandra ; Faath, Stefan ; Mich JF - Vaccine. 19 (2001), H. 20 Y1 - 2001 SN - 0264-410X SP - 4276 EP - 4286 ER - TY - JOUR A1 - Spiess, Elmar A1 - Wilfried, Reichardt A1 - Alvarez, Gerardo A1 - Gottrup, Marcus A1 - Öhlschläger, Peter T1 - An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma JF - Molecular Therapy Y1 - 2011 SN - 1525-0016 VL - 20 IS - 3 SP - 555 EP - 564 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Öhlschläger, Peter A1 - Pes, Michaela A1 - Osen, Wolfram A1 - Dürst, Matthias T1 - An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response / Öhlschläger, Peter ; Pes, Michaela ; Osen, Wolfram ; Dürst, Matthias ; Schneider, Achim ; Gissmann, Lutz ; Kaufman JF - Vaccine. 24 (2006), H. 15 Y1 - 2006 SN - 0264-410X SP - 2880 EP - 2893 ER - TY - JOUR A1 - Almajhdi, Fahad N. A1 - Senger, Tilo A1 - Amer, Haitham M. A1 - Gissmann, Lutz A1 - Öhlschläger, Peter T1 - Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (Shuffling) JF - PLOS one N2 - Persistent infection with the high-risk Human Papillomavirus type 16 (HPV 16) is the causative event for the development of cervical cancer and other malignant tumors of the anogenital tract and of the head and neck. Despite many attempts to develop therapeutic vaccines no candidate has entered late clinical trials. An interesting approach is a DNA based vaccine encompassing the nucleotide sequence of the E6 and E7 viral oncoproteins. Because both proteins are consistently expressed in HPV infected cells they represent excellent targets for immune therapy. Here we report the development of 8 DNA vaccine candidates consisting of differently rearranged HPV-16 E6 and E7 sequences within one molecule providing all naturally occurring epitopes but supposedly lacking transforming activity. The HPV sequences were fused to the J-domain and the SV40 enhancer in order to increase immune responses. We demonstrate that one out of the 8 vaccine candidates induces very strong cellular E6- and E7- specific cellular immune responses in mice and, as shown in regression experiments, efficiently controls growth of HPV 16 positive syngeneic tumors. This data demonstrates the potential of this vaccine candidate to control persistent HPV 16 infection that may lead to malignant disease. It also suggests that different sequence rearrangements influence the immunogenecity by an as yet unknown mechanism. Y1 - 2014 U6 - http://dx.doi.org/10.1371/journal.pone.0113461 SN - 1932-6203 VL - 11 IS - 9 PB - PLOS CY - San Francisco ER - TY - JOUR A1 - Leurs, Ulrike A1 - Mezo, Gabor A1 - Öhlschläger, Peter A1 - Orban, Erika A1 - Marquard, Andrea A1 - Manea, Marilena T1 - Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety JF - Peptide Science N2 - Bioconjugates containing the GnRH-III hormone decapeptide as a targeting moiety are able to deliver chemotherapeutic agents specifically to cancer cells expressing GnRH receptors, thereby increasing their local efficacy while limiting the peripheral toxicity. However, the number of GnRH receptors on cancer cells is limited and they desensitize under continuous hormone treatment. A possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of the bioconjugates would be the attachment of more than one chemotherapeutic agent to one GnRH-III molecule. Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing GnRH-III as a targeting moiety and daunorubicin as a chemotherapeutic agent. Two different drug design approaches were pursued. The first one was based on the bifunctional [4Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH2) containing two lysine residues in positions 4 and 8, whose ϵ-amino groups were used for the coupling of daunorubicin. In the second drug design, the native GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2) was used as a scaffold; an additional lysine residue was coupled to the ϵ-amino group of 8Lys in order to generate two free amino groups available for conjugation of daunorubicin. The in vitro stability/degradation of all synthesized compounds was investigated in human serum, as well as in the presence of rat liver lysosomal homogenate. Their cellular uptake was determined on human breast cancer cells and the cytostatic effect was evaluated on human breast, colon and prostate cancer cell lines. Compared with a monofunctional compound, both drug design approaches resulted in multifunctional bioconjugates with increased cytostatic effect. Y1 - 2012 U6 - http://dx.doi.org/10.1002/bip.21640 SN - 1097-0282 VL - 98 IS - 1 SP - 1 EP - 10 PB - Wiley CY - New York, NY ER - TY - JOUR A1 - Manea, Marilena A1 - Leurs, Ulrike A1 - Orban, Erika A1 - Baranyai, Zsuzsa A1 - Öhlschläger, Peter A1 - Marquardt, Andreas A1 - Schulcz, Akos A1 - Tejeda, Miguel T1 - Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4 JF - Bioconjugate Chemistry Y1 - 2011 SN - 1520-4812 VL - 22 IS - 7 SP - 1320 EP - 1329 PB - ACS CY - Washington, DC ER - TY - JOUR A1 - Öhlschläger, Peter A1 - Quetting, Michael A1 - Alvarez, Gerardo A1 - Dürst, Matthias A1 - Gissmann, Lutz A1 - Kaufmann, Andreas M. T1 - Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants JF - International Journal of Cancer Y1 - 2009 SN - 1097-0215 VL - 125 IS - 1 SP - 189 EP - 198 PB - Wiley CY - Weinheim ER - TY - JOUR A1 - Schöning, Michael Josef A1 - Biselli, Manfred A1 - Selmer, Thorsten A1 - Öhlschläger, Peter A1 - Baumann, Marcus A1 - Förster, Arnold A1 - Poghossian, Arshak T1 - Forschung „zwischen“ den Disziplinen: das Institut für Nano- und Biotechnologien JF - Analytik news : das Online-Labormagazin für Labor und Analytik N2 - "Biologie trifft Mikroelektronik", das Motto des Instituts für Nano- und Biotechnologien (INB) an der FH Aachen, unterstreicht die zunehmende Bedeutung interdisziplinär geprägter Forschungsaktivitäten. Der thematische Zusammenschluss grundständiger Disziplinen, wie die Physik, Elektrotechnik, Chemie, Biologie sowie die Materialwissenschaften, lässt neue Forschungsgebiete entstehen, ein herausragendes Beispiel hierfür ist die Nanotechnologie: Hier werden neue Werkstoffe und Materialien entwickelt, einzelne Nanopartikel oder Moleküle und deren Wechselwirkung untersucht oder Schichtstrukturen im Nanometerbereich aufgebaut, die neue und vorher nicht bekannte Eigenschaften hervorbringen. Vor diesem Hintergrund bündelt das im Jahre 2006 gegründete INB die an der FH Aachen vorhandenen Kompetenzen von derzeit insgesamt sieben Laboratorien auf den Gebieten der Halbleitertechnik und Nanoelektronik, Nanostrukturen und DNA-Sensorik, der Chemo- und Biosensorik, der Enzymtechnologie, der Mikrobiologie und Pflanzenbiotechnologie, der Zellkulturtechnik, sowie der Roten Biotechnologie synergetisch. In der Nano- und Biotechnologie steckt außergewöhnliches Potenzial! Nicht zuletzt deshalb stellen sich die Forscher der Herausforderung, in diesem Bereich gemeinsam zu forschen und Schnittstellen zu nutzen, um so bei der Gestaltung neuartiger Ideen und Produkte mitzuwirken, die zukünftig unser alltägliches Leben verändern werden. Im Folgenden werden die verschiedenen Forschungsbereiche kurz zusammenfassend vorgestellt und vorhandene Interaktionen anhand von exemplarisch ausgewählten, aktuellen Forschungsprojekten skizziert. Y1 - 2012 VL - Publ. online PB - Dr. Beyer Internet-Beratung CY - Ober-Ramstadt ER - TY - JOUR A1 - Whitehead, Mark A1 - Öhlschläger, Peter A1 - Almajhdi, Fahad N. A1 - Alloza, Leonor A1 - Marzábal, Pablo A1 - Meyers, Ann E. A1 - Hitzeroth, Inga I. A1 - Rybicki, Edward P. T1 - Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice JF - BMC cancer Y1 - 2014 U6 - http://dx.doi.org/10.1186/1471-2407-14-367 SN - 1471-2407 IS - 14:367 SP - 1 EP - 15 PB - BioMed Central CY - London ER - TY - JOUR A1 - Öhlschläger, Peter A1 - Osen, Wolfram A1 - Dell, Kerstin A1 - Faath, Stefan T1 - Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice / Öhlschläger, Peter ; Osen, Wolfram ; Dell, Kerstin ; Faath, Stefan ; Garcea Robert L: ; Jochmus, Ingrid ; Müller, Martin, Pawlita, JF - Journal of Virology. 77 (2003), H. 8 Y1 - 2003 SN - 1098-5514 SP - 4635 EP - 4645 ER -